Search results
Results From The WOW.Com Content Network
TTD includes information about successful, clinical trial and research targets, approved, clinical trial and experimental drugs linked to their primary targets, new ways to access data by drug mode of action, recursive search of related targets or drugs, similarity target and drug searching, customized and whole data download, and standardized ...
This choice would aid drug-discovery for the selected targets, as well as the development of both ligand-based and structure-based methods of computational ligand-design. This is the current focus of BindingDB, which is led by Michael Gilson , based at UC San Diego 's Skaggs School of Pharmacy and Pharmaceutical Sciences , and supported by a ...
Given its ability to capture a wide array of cellular responses, the Cell Painting assay has become a powerful tool in the field of drug discovery. [9] By comparing the morphological profiles of cells treated with different compounds, researchers can identify potential drug candidates, toxicity [10] or understand the mechanism of action of existing drugs.
Version 3.0 also included drug transporter data, drug pathway data, drug pricing, patent and manufacturing data as well as data on >5000 experimental drugs. Version 4.0 was released in 2014. [ 4 ] This version included 1558 FDA-approved small molecule drugs, 155 biotech drugs and 4200 unique drug targets.
The datasets are classified, based on the licenses, as Open data and Non-Open data. The datasets from various governmental-bodies are presented in List of open government data sites. The datasets are ported on open data portals. They are made available for searching, depositing and accessing through interfaces like Open API. The datasets are ...
The Comparative Toxicogenomics Database (CTD) is a public website and research tool that curates scientific data describing relationships between chemicals, genes/proteins, diseases, taxa, phenotypes, GO annotations, pathways, and interaction modules, launched on November 12, 2004.
Davis reagent (3-phenyl-2-(phenylsulfonyl)-1,2-oxaziridine or 2-(benzenesulfonyl)-3-phenyloxaziridine) is a reagent used for oxidation in the Davis oxidation reaction, [1] as well as oxidation of thiols to sulfones. [2]
CRLX101 is an experimental approach to cancer chemotherapy that is under investigation in human trials. It is an example of a nanomedicine.. The agent represents a nanoparticle conjugate that consists of a drug delivery molecule, namely a cyclodextrin-based polymer (CDP) and an anti-cancer compound (camptothecin).